ARWR analyst estimates
Arrowhead (ARWR) analyst ratings, the average price target and its range, and every firm's latest call.
ARWR analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 15, 2026 | UBS | Arrowhead assumed with a Buy at UBS | $109.00 |
| Sep 24, 2026 | Goldman Sachs | Arrowhead resumed with a Neutral at Goldman Sachs | $74.00 |
| Aug 31, 2026 | RBC Capital | RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR) | $100.00 |
| Aug 6, 2026 | H.C. Wainwright | Arrowhead price target raised to $120 from $115 at H.C. Wainwright | $120.00 |
| Aug 5, 2026 | Stifel Nicolaus | Arrowhead price target raised to $104 from $98 at Stifel | $104.00 |
| Jul 27, 2026 | H.C. Wainwright | Arrowhead price target raised to $115 from $100 at H.C. Wainwright | $115.00 |
| Jul 23, 2026 | Piper Sandler | Arrowhead price target raised to $126 from $110 at Piper Sandler | $126.00 |
| Jul 23, 2026 | Morgan Stanley | Arrowhead price target raised to $120 from $100 at Morgan Stanley | $120.00 |
| Jul 22, 2026 | Chardan Capital | Arrowhead price target raised to $115 from $90 at Chardan | $115.00 |
| Jul 13, 2026 | Stifel Nicolaus | Arrowhead initiated with a Buy at Stifel | $98.00 |
| May 13, 2026 | Bernstein | Arrowhead price target raised to $46 from $35 at Bernstein | $46.00 |
| May 8, 2026 | Chardan Capital | Arrowhead price target raised to $90 from $80 at Chardan | $90.00 |
| Apr 21, 2026 | Morgan Stanley | Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley | $100.00 |
| Feb 6, 2026 | Morgan Stanley | Arrowhead price target lowered to $78 from $81 at Morgan Stanley | $78.00 |
| Jan 27, 2026 | Robert W. Baird | Morgan Stanley on Arrowhead Pharma (ARWR): 'we are encouraged by the on track progress for the ARO-DIMER-PA program' | $81.00 |
- 13 firms rate ARWR: 10 buy, 3 hold, 0 sell.
- The average price target is $101.56 from 9 analysts, from $46.00 to $126.00.
Updated 2026-11-02 23:59 UTC